A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Study sponsor: Lakefront Biotherapeutics NV · LKFT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-10-09Actual
Enrollment · participants22Actual
Source updated2024-10-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.